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ABSTRACT 
Background: The microbiome is strongly linked to many extra-intestinal disorders. Gut commensal microbiota, in 
particular, plays an active role in human immune and intestinal homeostasis. Complex interactions of the microbiota with 
host genetics and other underlying factors lead to intestinal dysbiosis, which is thought to be linked to ocular inflammatory 
diseases. Thus, the aim of this review is to analyze the role of intestinal microbiome in age-related macular degeneration 
(AMD). 
Methods: A thorough literature search was performed using PubMed/MEDLINE, limited to English language publications, 
from January 2004 to March 2020. An additional search was made employing Google Scholar to complete the collected 
data as per the above-mentioned time-line and language limitations. The main keywords used included age-related 
macular degeneration, microbiome, dysbiosis, autoimmunity, gut microbiota, epigenetics, immune-mediated 
inflammatory diseases, and gut-retina axis. 
Results: Recent studies have proposed the role of intestinal microbiota in the pathogenesis of AMD. Changes in the microbiome 
have been shown to trigger several ocular inflammatory processes. There is increasing evidence demonstrating that intestinal 
microbial imbalance may play an important role in the pathogenesis of AMD. 
Conclusions: This review summarizes how alterations in the intestinal microbiota can be associated with the pathogenesis 
of AMD and how new therapeutic modalities can be designed to target this microbiome to limit the severe nature of this 
disease. Future advances in microbiome research may unveil a new era in understanding and managing AMD. 
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INTRODUCTION 
A microbiome consists of microorganisms coexisting 
symbiotically within the human body and their genetic 
material [1, 2]. Most of these microorganisms reside in the 
small and large intestines. The gastrointestinal (GI) tract 
has been found to contribute to 70% of our body’s 
immune system. Every individual has a specific meshwork 
of microbiota that is predetermined by its own DNA, thus 
making microbiota of each person unique. In the past, it 
was believed that these microorganisms were passive 
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known that they play a very important role in early 
postnatal mucosal and systemic immunity, as well as 
contribute to homeostasis of the immune system. This has 
been revealed through experimental studies that 
associate the microbiome of the intestines to its control of 
both innate and adaptive immune responses. Intestinal 
microbiome dysbiosis, which is an imbalance between 
beneficial and harmful microbes of the intestinal tract, has 
been associated with various diseases, such as 
rheumatoid arthritis, cardiovascular disease, type 1 
diabetes, multiple sclerosis, and spondyloarthritis [1, 2]. 
For example, some specific strains of segmented 
filamentous bacteria of the gut microbiota of rodents [3] 
and similar bacterial strains of human gut microbiota [3] 
have been found to regulate differentiation of colonic 
regulatory T cells (Tregs) and T helper cell 17 (Th17) in the 
gut. Pathogenic Th17 cells are strongly related to 
inflammatory diseases such as arthritis and non-infectious 
uveitis. However, differentiation of Tregs plays an 
important role in homeostasis of the immune system [1]. 
This differentiation is produced by specific strains of 
Clostridia and Bacteroides fragilis. Furthermore, short 
chain fatty acids (SCFAs) that result from the fermentation 
process of nutritional fibers or those derived from 
exogenous routes increase the predominance of Tregs in 
the intestines and also have a protective role against T-
cell‒mediated colitis [1]. Moreover, due to a specific 
balance between symbiosis of microorganisms in the gut, 
any differences in the intestinal barrier activity, 
reinforcement, or debilitation would increase intestinal 
permeability. Thus, the aim of this review was to analyze 
the role of intestinal microbiome in age-related macular 
degeneration (AMD).  
METHODS 
A thorough literature search was performed using the 
PubMed/MEDLINE bibliographic database from January 
2004 to March 2020. Papers in languages other than 
English were excluded. An additional search was 
performed employing Google Scholar to complete the 
collected items as per the above-mentioned time-line and 
language limitations. The main keywords used included 
‘age-related macular degeneration’, ‘microbiome’, 
‘dysbiosis, autoimmunity’, ‘gut microbiota’, ‘epigenetics’, 
‘immune-mediated inflammatory diseases’, and ‘gut-
retina axis’.  
RESULTS 
A critical appraisal was conducted for papers published 
between 2004 and 2020, with special emphasis on studies 
published within the last five years. Table 1 summarizes 
the characteristics of  articles related to the role of 
intestinal microbiome in the pathogenesis of AMD that 
are included in this review. 
DISCUSSION 
Microbiome Dysbiosis and Human Health 
Numerous hypotheses on how gut microbiota can initiate 
an inflammatory process distal from the intestinal tract 
have been proposed. The first hypothesis is that 
differentiation in T-cell population leads to harmful 
intestinal bacteria, overcoming the beneficial ones. This 
results in an abnormal immune response, which increases 
immune regulatory cell types (e.g., Th17) and decreases 
immune regulatory cell types such as Tregs. Consequently, 
the activation threshold of Th17 cells decreases, and their 
numbers increase in different parts of the body. If the 
environment is ideal for bacterial growth, they can 
become pathogenic [4].  
Another hypothesis is that stimulation of tissue-reactive T-
cells by self-antigens and commensal peptides, through 
their cross-reactivity, leads to immune-mediated diseases 
[5]. Finally, another hypothesis states that dysbiosis may 
occur between different microbes in the intestines, 
leading to increased permeability of the intestinal barrier 
either for harmful bacteria or non-specific bacterial 
antigens. As they travel through the blood stream or the 
lymphatics, they can cause dysregulation of extra-
intestinal acquired immune responses [6]. Several studies 
have also found a causative link between host genetics, 
HLA-type, and the gut microbiome [3, 6]. 
Over the past few years, several studies have explored the 
correlation between changes in the gut microbiome and 
intestinal or extra-intestinal immune-mediated disorders, 
such as inflammatory bowel disease, irritable bowel 
syndrome, obesity, rheumatoid arthritis, ankylosing 
spondylitis, multiple sclerosis, autoimmune uveitis, types 
1 and 2 diabetes, and AMD [1-3, 7].  
Zinkernagel et al. [8] found an abundance of 
Anaerotruncus spp., Oscillibacter spp., Eubacterium 
ventriosum, and Ruminococcus torques in patients with 
neovascular AMD  than in control groups who exhibited an 
abundance of Bacteroides eggerthii instead, which has a 
protective role against immune-mediated diseases. Lin et 
al. [9] found an increased number of Prevotella spp. and a 
reduced number of Rikenellaceae populations. Therefore, 
it of interest to further investigate the gut microbiome and 
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Table 1. Characteristics of Included Articles Related to the Role of Intestinal Microbiome in the Pathogenesis of Age-Related Macular Degeneration 
  
No. Study  Title Journal Date of 
publish 
Type of study 
1 Lin P [1]  Importance of the intestinal microbiota in ocular inflammatory diseases: A review. Clin Exp Ophthalmol. 2019 Review 
2 Baim AD et al. [2] The microbiome and ophthalmic disease. Exp Biol Med (Maywood) 2019 Review 
3 Lin P [3] The role of the intestinal microbiome in ocular inflammatory disease. Curr Opin Ophthalmol. 2018 Review 
4 Belkaid Y et al. [4] Role of the microbiota in immunity and inflammation. Cell 2014 Review 
5 Chervonsky AV [5]  Microbiota and Autoimmunity Cold Spring Harb 
Perspect Biol. 
2013 Review 
6 Zheng D et al. [6]  Interaction between microbiota and immunity in health and disease. Cell Res. 2020 Review 
7 Forbes JD et al. [7]  The Gut Microbiota in Immune-Mediated Inflammatory Diseases Front Microbiol. 2016 Review 
8 Zinkernagel MS et al. 
[8]  
Association of the Intestinal Microbiome with the Development of Neovascular 
Age-Related Macular Degeneration. 
Sci Rep. 2017 Metagenome analysis 
9 Lin P et al. [9]  HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. PLoS One. 2014 Experimental study 
10 Nayyar A et al. [10]  Do epigenetic changes caused by commensal microbiota contribute to 
development of ocular disease? A review of evidence. 
Hum Genomics. 2020 Review 
11 Andriessen EM et al. 
[11]  
Gut microbiota influences pathological angiogenesis in obesity-driven choroidal 
neovascularization. 
EMBO Mol Med. 2016 Experimental study 
12 Rowan S et al [12] Gut microbiota modify risk for dietary glycemia-induced age-related macular 
degeneration. 
Gut Microbes 2018 Experimental study 
(metabolomics study) 
13 Carneiro Â et al. [13] Nutritional and Lifestyle Interventions for Age-Related Macular Degeneration: A 
Review 
Oxid Med Cell Longev. 2017 Review 
14 Margrain TH et al. [14] Do blue light filters confer protection against age-related macular degeneration? Prog Retin Eye Res. 2004 Review 
15 de Jong PT [15] Age-related macular degeneration. N Engl J Med. 2006 Review 
16 Zhang QY et al. [16] Overweight, Obesity, and Risk of Age-Related Macular Degeneration. Invest Ophthalmol Vis 
Sci. 
2016 Review 
17 Peeters A et al. [17] Changes in abdominal obesity and age-related macular degeneration: the 
Atherosclerosis Risk in Communities Study. 
Arch Ophthalmol. 2008 Population-based 
cohort study 
18 Chiu CJ et al. [18] Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog Retin Eye Res. 2011 Review 
19 Rinninella E et al [19] The Role of Diet, Micronutrients and the Gut Microbiota in Age-Related Macular 
Degeneration: New Perspectives from the Gut⁻Retina Axis. 
Nutrients 2018 Review 
20 Lau K et al. [20] Bridging the Gap between Gut Microbial Dysbiosis and Cardiovascular Diseases. Nutrients 2017 Review 
21 Ma J et al. [21] Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and 
Therapy. 
Nutrients 2017 Review 
22 Ponziani FR et al. [22] Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and 
Inflammation in Nonalcoholic Fatty Liver Disease.  
Hepatology 2019 Prospective study 
23 Turnbaugh PJ et al. 
[23] 
An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006 Comparative study 
24 Adams MK et al. [24] Abdominal obesity and age-related macular degeneration. Am J Epidemiol. 2011 Prospective cohort 
study 
25 Clarke SF et al. [25] The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes. 2012 Review 
26 Rabot S et al. [26] Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance 
and have altered cholesterol metabolism. 
FASEB J. 2010 Experimental study 
27 Ticinesi A et al. [27] Aging Gut Microbiota at the Cross-Road between Nutrition, Physical Frailty, and 
Sarcopenia: Is There a Gut-Muscle Axis? 
Nutrients 2017 Review 
28 Evans JR et al. [28] Antioxidant vitamin and mineral supplements for slowing the progression of age-
related macular degeneration. 
Cochrane Database Syst 
Rev. 
2017 Systematic Review 
29 Abd AJ et al. [29] Aged macular degeneration: current therapeutics for management and promising 
new drug candidates. 
Drug Discov Today 2017 Review 
30 Ahmadi M et al. [30] Epigenetic modifications and epigenetic based medication implementations of 
autoimmune diseases. 
Biomed Pharmacother. 2017 Review 
31 Ramadoss M et al. [31] Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discov Today 2018 Review 
32 Cheung K et al. [32] BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation 
and ameliorates colitis in mice. 
Proc Natl Acad Sci   2017 Experimental study 
33 Eskandarpour M et al. 
[33] 
Pharmacological Inhibition of Bromodomain Proteins Suppresses Retinal 
Inflammatory Disease and Downregulates Retinal Th17 Cells. 
J Immunol. 2017 Experimental study 
34 Hammitzsch A et al. 
[34] 
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 
responses. 
Proc Natl Acad Sci U S A. 2015 Experimental study 
35 Wen X et al. [35] Epigenetics, microbiota, and intraocular inflammation: New paradigms of immune 
regulation in the eye. 
Prog Retin Eye Res. 2018 Review 
36 Markowiak P et al. [36] Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017 Review 
37 Gilbert JA et al. [37] Microbiome-wide association studies link dynamic microbial consortia to disease. Nature 2016 Review 
38 Zegans ME et al. [38] Considerations in understanding the ocular surface microbiome. Am J Ophthalmol. 2014 Editorial 
39 Dong Q et al. [39] Diversity of bacteria at healthy human conjunctiva. Invest Ophthalmol Vis 
Sci. 
2011 DNA sequencing-based 
study 
40 Lu LJ et al. [40] Human Microbiota and Ophthalmic Disease. Yale J Biol Med. 2016 Review 
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The Gut-Eye Axis:  Intestinal Microbiome in AMD 
AMD is one of the most common causes of blindness in 
the elderly population. Although its pathogenesis is 
unclear, genetic and environmental factors, such as a 
Western diet (a high-caloric, high-fat, and simple sugar-
based diet), a diet low in omega-3 fatty acids, smoking, as 
well as genetic variants of complement and genes related 
to other inflammatory  or lipid pathways are thought to be 
involved. Some inflammatory mechanisms linked to 
innate immunity such as NLR family pyrin domain 
containing 3 (NLRP3) receptors, complement pathways, 
and tool-like receptors may play a role in the progression 
of AMD. These pathways are strongly linked to human 
commensal intestinal microbiota [1]. 
In the largest genome-wide study on AMD patients, 
genetic variants were observed to be associated with the 
disease at 34 loci. These data are only a part of the 
genomic heritability of AMD. Of these variants, the ones 
most strongly linked to AMD were the complement 
pathway gene variants, such as the complement factor H 
(CFH) and complement factor I (CFI) genes (both 
regulators of the complement cascade), as well as age-
related maculopathy susceptibility 2 (ARMS2) gene. Other 
gene variants, for example, lipid-associated pathway 
genes such as apolipoprotein E (Apo E), and the hepatic 
lipase (LIPC), which represent the lipid metabolism 
pathway and tissue inhibitor of metalloproteinase 3 
(TIMP3), were associated with AMD. All patients with 
AMD also have drusen, which contains complement 
lipoproteins and lipids. They also usually present with 
overactivity of the complement. Studies have shown that 
alterations in intestinal microbiome are thought to be an 
environmental causative agent for elevated levels of 
complement through the complement cascade [1]. 
Besides, genetic risk factors of AMD, environmental 
factors such as diet, smoking, and hypertension also play 
an important role in the progression of AMD. Accordingly, 
suggestions provided by the Age-Related Eye Disease 
Study (AREDS) and AREDS2  on diet modifications have 
slowed down the progression of dry AMD to wet AMD in 
some patients. Intestinal microbiota also appear to have 
an impact on the dietary intake of nutrients [10].  
Intestinal microbiome dysbiosis often occurs along with 
chronic inflammation and enhanced intestinal 
permeability. This is followed by elevated levels of 
pathogen-associated molecular pattern molecules 
(PAMPs) and bacterial by-products in the circulation, 
triggering an immune response through their interaction 
with pattern recognition receptors (PRRs). PRRs are also 
expressed in ocular cells, leading to ocular inflammation. 
These data signify a connection between AMD and 
dysbiosis of the gut microbiome [10]. 
Animal studies, such as that of Andriessen et al., have 
shown an association between alterations in gut 
microbiome, choroidal neovascularization (CNV), and diet 
in mice. They evaluated this hypothesis by transplanting 
gut microbiota from mice fed a regular diet into mice fed 
a high-fat diet. A high-fat diet appeared to increase the 
progression of CNV; however, the progression decreased 
when the Bacteroidetes/Firmicutes ratio in intestinal 
microbiome increased in the regular diet-fed mice. A 
study revealed that oral administration of an antibiotic, 
neomycin, changed the bacterial flora in mice fed a high-
fat diet, leading to a delayed progression of CNV [11]. 
In another animal study by Rowan et al., mice 
administered a high-glycemic index diet showed increased 
levels of dry AMD features compared to those fed a low-
glycemic index diet. The authors also described some 
alterations in intestinal microbiota between the two 
groups. Serotonin, a tryptophan metabolite, which is 
thought to have an inhibitory effect on AMD features, was 
elevated in mice fed a low-glycemic index diet. These 
findings support the concept of a gut-retina axis, in which 
alterations in intestinal microbiota via diet, probiotics, or 
antibiotics influence the onset and progression of AMD 
[12]. 
Dietary Factors and Gut-Microbiota in AMD 
Although pathogenetic mechanisms of AMD have not yet 
been clearly defined, there are studies showing that 
inflammation may play a role in its pathogenesis. The 
retinal pigment epithelium (RPE) is exposed to high 
oxygenation levels. High levels of unsaturated fatty acids 
and photosensitizing compounds have been shown to 
cause retinal damage via adverse effects of reactive 
oxygen species (ROS) [13]. Light exposure, including 
ambient natural light, induces the formation of ROS in the 
RPE and is considered to be one of the less recognizable 
but common risk factors of AMD [14]. Smoking, given its 
pro-oxidative and pro-inflammatory effects, is a more 
recognizable modifiable risk factor of AMD [15].  
Pathogenesis and progression of AMD have been 
associated with a wide range of factors, including age, 
environmental factors, genetics, lifestyle, and diet.   
Excess weight has been linked to a higher risk of AMD and 
shows a dose-dependent trend [16, 17], and excess sugar 
consumption related to modern dietary habits has also 
been correlated with AMD [18]. Contribution of various 
nutritional and non-nutritional compounds (that exceed 
the essential energy intake) in AMD has been 
demonstrated in several epidemiological studies [19] .  
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Nutrients may have a direct antioxidant or anti-
inflammatory effect, or act indirectly through the gut 
microbiome [19]. This has led to an interest in the efficacy 
of nutraceuticals and functional foods rich in prebiotics 
and antioxidants in the prevention and supplementation 
of anti-AMD pharmacological treatments [19].  
Over the last decade, intestinal dysbiosis has been 
associated with a wide spectrum of intestinal and extra-
intestinal pathologies, including inflammatory and 
metabolic diseases, non-alcoholic fatty liver disease 
(NAFLD), obesity, and cancer [20-24]. Increased gut 
permeability allows excessive translocation of bacterial 
products, such as PAMPs and endotoxin 
lipopolysaccharides, which leads to low-grade 
inflammation in various tissues via the activation of PRRs. 
Interestingly, this biological crosstalk is also observed in 
perivascular macrophages, dendritic cells, and RPE cells, 
contributing to the ocular inflammatory process. 
Additionally, retina-specific immune cells have been 
observed to be regulated by metabolites of intestinal 
microbiota, whereas obesity-related gut microbiota has 
been found to cause pathological angiogenesis and 
eventually CNV in retinal tissue [11]. 
Evidence from experimental studies has shown that ob/ob 
mice (mutant mice that consume excessive amounts of 
food because of mutations in the leptin gene) exhibit a 
50% decrease in Bacteroidetes and an increase in 
Firmicutes compared to lean mice [24].  Administering a 
Western diet to wild-type mice reduced the diversity of 
intestinal microbiota, especially of Bacteroidetes, and 
displayed an increase in a single class of Firmicutes 
(Mollicutes) [25]. This “obesity-associated gut 
microbiome” has been demonstrated to have an 
increased propensity to recruit energy from diet by 
breaking down otherwise indigestible dietary 
polysaccharides [23]. Interestingly, this increased 
adiposity revealed to be a transmissible feature: adult 
germ-free mice colonized (by gavage) with microbiota of 
obese (ob/ob) donors demonstrated a substantially higher 
increase in body fat over a two-week period compared to 
mice colonized with microbiota from lean donors fed with 
food having the same quantity and caloric density [23]. 
Furthermore, a high-fat diet does not lead to 
hypercholesterolemia or weight gain in the absence of gut 
microbiota, as exhibited in germ-free C57BL/6J mice 
compared to wild-type mice. Another trait of germ-free 
mice is that they show improved insulin sensitivity and 
improved glucose tolerance compared to conventional 
mice [26]. These findings validate the fact that gut 
microbiota plays a critical role in metabolic pathways of 
low-grade inflammation and obesity. After the age of 65 
years, intestinal microbiota in humans has been shown to 
undergo important alterations that affect its resilience to 
antibiotics or diseases. This is especially true in frail 
patients [27]. Besides, gut microbiota is a critical 
parameter that plays a role in the absorption and 
metabolism of macro- and micronutrients, especially 
microbiota related to AMD [27]. The use of vitamins and 
other anti-oxidative micronutrients can reduce the risk of 
AMD due to their anti-inflammatory and antioxidant 
properties [28]. However, the impact of high-fat, high-
glucose, or fructose diets, as well as the role of substances 
such as micronutrients, vitamins (C, D, and E), carotenoids, 
lutein, zeaxanthin, and omega-3 fatty acids need further 
research to prove their effects.  
The current published evidence has shown that the 
concept of “gut-retina axis” exists in the pathogenesis of 
AMD [1-3]. It appears that an interplay among diet, 
micronutrients, gut microbiota, and host immunity is a 
new frontier in the treatment of several other metabolic 
disorders. However, the exact effect of these dietary 
parameters on gut microbiota and the pathogenesis of 
AMD is beyond the scope of this review. 
Therapeutic Targeting of Intestinal Microbiome for 
Ocular Inflammatory Disease 
The activity of microorganisms present in the eye can 
trigger intraocular inflammation. The triggering of 
immune responses is linked with alterations of 
epigenomes in cells associated with innate and adaptive 
immunity, leading to the production of immune mediators 
(such as cytokines), recruitment of immune cells to the 
site of inflammation, and finally destruction and/or 
recovery of the tissues. Therefore, various therapeutic 
approaches have been developed to suppress intraocular 
inflammatory activity. In AMD, intravitreal anti-vascular 
endothelial growth factor (VEGF) agents are used to 
prevent the progression of CNV and eventually vision 
impairment in patients with wet AMD. However, effective 
therapeutic modalities for dry AMD are yet to be 
discovered [29].  
Recent advances in the field of epigenetic drugs that 
target epigenetic machinery, including writers, readers, 
and erasers of epigenetic modifications, may lead to  new 
tools for immunosuppressive treatment [30]. Among 
these drugs, histone methyltransferase inhibitors (HMTis), 
histone deacetylase inhibitors (HDACis), DNA 
methyltransferase inhibitors (DNMTis), and bromodomain 
extra-terminal (BET) inhibitors have been approved for 
the treatment of other clinical diseases, such as 
malignancies [31]. In addition, various compounds, such 
as JQ1 (a bromodomain inhibitor) [32-34], have shown 
promising immunosuppressive effects in the real world. 
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The success of these drugs relies on their potential effect 
on controlling intraocular inflammation after local or 
systemic administration. Specificity of these epigenetic 
drugs is derived from their ability to target the cell types 
of specific epigenetic regulatory networks. Furthermore, 
they can control multiple cytokines and immune 
mediators rather than a single cytokine, which further 
enhances their effectiveness in controlling intraocular 
inflammation [35].  
Although the pathogenetic background of AMD related to 
infection has garnered much attention, targeting 
microbiota for designing new treatments still remains 
debatable. Attempts to restore intraocular and 
extraocular imbalance of microbiota may lead to further 
problems due to the development of resistance to 
antibiotics, especially when they are used to eliminate 
pathogenic bacteria, resulting in other ocular diseases. 
Recent studies have suggested that combined therapies 
with probiotics and prebiotics have a great potential to 
treat dysbiosis of gut microbiota [36]. 
The present review, albeit its strengths, has several 
limitations. This study is a review of literature on the 
correlation between AMD and gut microbiota. As 
summarized in Table 1, this review covers a wide spectrum 
of aspects regarding this issue without duplication of data. 
Most of the references included in this review comprised 
studies published within the last five years. In addition, 
special emphasis was placed on reports that provided the 
most updated information. However, in the present 
literature review, there is a possibility that all relevant 
literature has not been included, thus increasing the 
probability of bias in concluding the data. Additionally, the 
number of human studies is limited, and most of our 
knowledge regarding the impact of microbiome on AMD 
is based on experimental data. 
Future perspectives on the microbiome of human body 
will be worth noting, and recognizing its importance will 
improve our understanding of the pathogenesis of several 
immune-mediated human diseases. Refinement of 
laboratory and experimental techniques has also enabled 
researchers to define compositional and functional 
aspects of these microbiotas. New assays and 
bioinformatic studies have allowed a more detailed 
analysis of host-microbiota interactions, whereas large-
scale longitudinal studies have provided new insights 
regarding the effect of microbiotas on various 
pathogenetic mechanisms. Nevertheless, clinical trials are 
essential for investigating microbiotas as potential 
biomarkers and uncovering their potential role in the 
prevention or treatment of immune-mediated diseases [2, 
37]. The microbiome related to ophthalmology has 
opened up a new field of research; however, it is yet to be 
determined how it can be used in treating ophthalmic 
diseases in humans [38-40]. Implementation of methods 
gained from other fields of microbiome research would be 
invaluable in exploring the pathogenesis of 
ophthalmological diseases. Gaining insights into host 
biology can contribute to understanding whether 
microorganisms are temporarily present and are rapidly 
inactivated or whether they are persistently present, 
leading to more permanent and active communities. 
Gnotobiotic animal models used in microbiome research 
may also be helpful in conducting ophthalmological 
research in this field [37]. However, novel experimental 
techniques and larger clinical trials have established a 
more solid connection between basic science and 
observational research in this field. 
Further experimental investigations may uncover an 
association between extraocular microbiome and ocular 
diseases, or even ophthalmic interventions (e.g., 
intravitreal injections of anti-VEGF and topical instillation 
of cyclosporine), which may potentially affect ocular 
microbiota).  
CONCLUSION 
Increasing evidence has revealed that an imbalance 
between beneficial and harmful microbes of intestinal 
microbiota or intestinal dysbiosis may play an important 
role in the pathogenesis of AMD. Defining the exact role 
of intestinal microbiome will help us understand 
pathogenetic mechanisms and indicate potential 
treatment options for AMD. Targeting gut microbiota via 
dietary alterations, probiotics, bacterial metabolite 
supplementation, fecal microbial transplantation, or 
antibiotics could be a potential option for preventing the 
progression of AMD. With time and larger longitudinal 
animal and clinical studies, future advances in microbiome 
research will be promising and may unveil a new era in the 
treatment of AMD. 
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